Company / Capital Expenditures
NovaBay Pharmaceuticals, Inc. Capital Expenditures History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$6.0K
FY2024
5-year range
$6.0K / $112.0K
FY2020-FY2024
Trend
-68.4%
vs FY2023
Sector context
#186 of 192
Health Care
What the data says
Among 192 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 3% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $6,000 in FY2024 to $244,000 in FY2017.
Based on SEC 10-K filings.
$6,000 in FY2024 with a 5-year CAGR of -20.6%.
Declined from $112,000 to $6,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -51.3%
- 5-Year CAGR
- -20.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 192This company $6.0K Sector average $118.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -20.6%, indicating a declining trend.
- In FY2024, capital expenditures decreased 68.4% year-over-year.
- Ranks #186 out of 192 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.0K | -68.4% |
| FY2023 | $19.0K | -83.0% |
| FY2022 | $112.0K | +115.4% |
| FY2021 | $52.0K | +100.0% |
| FY2020 | $26.0K | +36.8% |
| FY2019 | $19.0K | -56.8% |
| FY2018 | $44.0K | -82.0% |
| FY2017 | $244.0K | +52.5% |
| FY2016 | $160.0K | +30.1% |
| FY2015 | $123.0K | +80.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026